Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt Acquires 12,829 Shares

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CFO Jonathan Robert Hunt bought 12,829 shares of the stock in a transaction on Monday, November 25th. The shares were acquired at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the transaction, the chief financial officer now directly owns 48,800 shares of the company's stock, valued at approximately $186,416. The trade was a 35.66 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Perspective Therapeutics Trading Up 18.4 %

Shares of CATX stock opened at $4.37 on Wednesday. Perspective Therapeutics, Inc. has a 52 week low of $2.28 and a 52 week high of $19.05. The business's fifty day simple moving average is $11.15.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million during the quarter. As a group, equities analysts predict that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC bought a new position in Perspective Therapeutics in the 3rd quarter valued at $57,000. US Bancorp DE raised its holdings in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after purchasing an additional 3,866 shares during the last quarter. Intech Investment Management LLC acquired a new position in Perspective Therapeutics during the 3rd quarter valued at about $137,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Perspective Therapeutics in the 3rd quarter valued at about $152,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Perspective Therapeutics during the third quarter worth approximately $153,000. Institutional investors own 54.66% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on CATX. Truist Financial initiated coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They set a "buy" rating and a $21.00 target price for the company. Bank of America downgraded shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $24.00 to $5.00 in a report on Monday. Cantor Fitzgerald restated an "overweight" rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Oppenheimer cut their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, November 22nd. Finally, UBS Group began coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They set a "buy" rating and a $20.00 target price for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $15.14.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.